ST. PETERSBURG, Florida, August 18, 2015—Lenstec, Inc.—an established medical device manufacturer of
technologically advanced implantable lenses for treating vision disorders—today announced the start of an
FDA trial in support of gaining FDA clearance for its Segmented Bi-focal lens (SBL-3).
technologically advanced implantable lenses for treating vision disorders—today announced the start of an
FDA trial in support of gaining FDA clearance for its Segmented Bi-focal lens (SBL-3).
RSS Feed